The flotation of US-based liver drugs maker Intercept Pharmaceuticals, majority owned by Genextra, came in October.
Intercept Pharmaceuticals, a US-based liver drugs maker based on work at Italy’s University of Perugia, has raised $75m in its initial public offering [IPO].
The flotation in October was advised by banks BofA Merrill Lynch, Needham & Co, Wedbush PacGrow, ThinkEquity and Life Sciences.
The company sold 5 million shares at $15 per share each, according to its filing with US regulator the Securities and Exchange Commission.
The company is majority-owned by Genextra (69.4% stake, pre-IPO), which was created…
